ArQule Reports Third Quarter 2016 Financial Results

Edit Stockhouse 07 Nov 2016
ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in ......

Global Market Report On O-Phospho-Dl-Threonine (CAS 27530-80-9) 2016 - Forecasts to 2020 - Research and Markets

Edit Business Wire 04 Nov 2016
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Market Report On O-Phospho-Dl-Threonine 2016" report to their offering. The Global Market Report on O-Phospho-Dl-Threonine provides comprehensive data on O-Phospho-Dl-Threonine global and regional markets including Europe, Asia, North America, Latin America The ......

Amino Acids China E-News 1607

Edit PR Newswire 03 Nov 2016
NEW YORK, Nov. 3, 2016 /PRNewswire/ -- July 2016 sees rises and falls in the market prices of major amino acids in China for various reasons. In particular, the price of lysine soars due to tight market supply. Meanwhile, some domestic threonine producers raised their quotations, ... ....

Evonik submits bid for METEX methionine technology platform (Evonik Industries AG)

Edit Public Technologies 03 Nov 2016
(Source ... Essen, Germany. Amino acids produced by fermentation are an important pillar of Evonik's product portfolio for sustainable animal nutrition. The production processes for Biolys® (lysine), ThreAMINO® (threonine) and TrypAMINO® (tryptophane) have been made continuously more efficient over the past years and the portfolio was just recently enlarged by launching ValAMINO® (valine) ... (noodl. 36127649) ....

Advancements in ArQule’s Proprietary Pipeline to be Highlighted at the 2016 American Society of Hematology ...

Edit Stockhouse 03 Nov 2016
ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in ......

ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016

Edit Stockhouse 24 Oct 2016
ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in ......

ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016 (ArQule Inc)

Edit Public Technologies 24 Oct 2016
ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in ......

Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up (Novartis AG)

Edit Public Technologies 08 Oct 2016
(Source ... The results of this study, which was conducted in 704 patients[1], are being presented at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen ... About Melanoma ... Tafinlar and Mekinist target different kinases within the serine/threonine kinase family - BRAF and MEK1/2, respectively - in the RAS/RAF/MEK/ERK pathway, which is implicated in non-small cell lung cancer (NSCLC) and melanoma, among other cancers....

ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016

Edit Stockhouse 21 Sep 2016
ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in ......

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 ...

Edit Business Wire 20 Sep 2016
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H2 2016" report to their offering. 'SerineThreonine Protein Kinase ATR - Pipeline Review, H2 2016'; Serine Threonine Protein Kinase ATR pipeline Target constitutes close to 7 molecules ... Serine/Threon ... ....

IICPT targets youths with trendy food items

Edit The Times of India 17 Sep 2016
TRICHY ... It also has a low glycemic index ... The nankhattai developed from quinoa is a gluten-free low glycemic index bakery product rich in amino acids such as lysine, threonine and methionine.Quinoa is also a very good source of protein, calcium and iron; the carbohydrate- protein ratio making it a prospective grain to combat malnutrition, the scientist said ... Stay updated on the go with Times of India News App ... RELATED....

ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer ...

Edit Stockhouse 15 Sep 2016
ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in ......

Enzymes Market size worth $10.7bn by 2024: Global Market Insights Inc.

Edit Nasdaq Globe Newswire 30 Aug 2016
Ocean View, Delaware, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Enzymes Market size is poised to hit USD 10.7 billion by 2024; according to a new research report by Global Market Insights, Inc. Growing demand for high nutrition diet along with lifestyle & demographic dynamics will stimulate global enzymes market size ... U.S ... Major proteases include serine, cysteine, threonine, aspartate, glutamic acid, papain, and metalloproteases ... Hansen, and ADM....
×